# US 2015/0031616 A1 · Use of relaxin to treat placental syndromes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031616 A1
- Document ID: US20150031616A1
- Status: Published application
- Kind: A1
- Application number: 14/340,858
- Filed: 2014-07-25
- Published: 2015-01-29
- Earliest claimed: 2013-07-25
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Inc.
- Inventors: KIRK P. CONRAD
- Web page: https://patentgrep.com/patent/US20150031616A1

## CPC

- A61K 38/2221: {Relaxins}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy.

## Claims

### Claim 1

A method for treating a placental syndrome in a woman comprising the steps of: (a) determining whether a woman has experienced a placental syndrome during a previous pregnancy; (b) if the woman has experienced a placental syndrome during a previous pregnancy, determining the late secretory/luteal (LS) phase of the menstrual cycle; and (c) administering a therapeutically effective amount of relaxin to the woman during the LS phase of menstruation to treat the placental syndrome.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the relaxin is an RXFP-1 agonist or mimetic.

### Claim 3 (depends on 1)

The method according to claim 1, wherein step (b) comprises administering an ovulation or fertility kit to the woman.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the therapeutically effective amount of relaxin is 0.1 to about 100 μg/kg of subject body weight per day.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the administration of the relaxin results in serum concentrations of relaxin of about 0.1-10.0 ng/ml during the LS phase of the menstrual cycle.

### Claim 6 (depends on 4)

The method according to claim 4, wherein administration of the relaxin results in serum concentrations of relaxin of about 0.1-3.0 ng/ml during the LS phase of the menstrual cycle.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising the step of (d) determining whether the woman is pregnant and (e) if the woman is determined to be pregnant following step (d), administering a therapeutically effective amount of relaxin to the woman through the 1st trimester of pregnancy.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the relaxin is a RXFP-1 agonist or mimetic.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the placental syndrome is preeclampsia.

### Claim 9

A method for treating a placental syndrome in a woman comprising the steps of: (a) diagnosing whether a woman will have a propensity for developing a placental syndrome; (b) if the woman is one who has a propensity for developing a placental syndrome, determining the late secretory/luteal (LS) phase of the menstrual cycle; and (c) administering a therapeutically effective amount of a relaxin to the woman during the LS phase of menstruation.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the relaxin is a RXFP-1 agonist or mimetic.

### Claim 11 (depends on 9)

The method according to claim 9, wherein step (b) comprises administering an ovulation or fertility kit to the woman.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the therapeutically effective amount of relaxin is 0.1 to about 100 μg/kg of subject body weight per day.

### Claim 13 (depends on 12)

The method according to claim 12, wherein administration of the relaxin results in serum concentrations of relaxin of about 0.1-10.0 ng/ml during the LS phase of the menstrual cycle.

### Claim 14 (depends on 12)

The method according to claim 12, wherein administration of the relaxin results in serum concentrations of relaxin of about 0.1-3.0 ng/ml during the LS phase of the menstrual cycle.

### Claim 15 (depends on 9)

The method according to claim 9, further comprising the step of (d) determining whether the woman is pregnant and (e) if the woman is determined to be pregnant following step (d), administering a therapeutically effective amount of relaxin (or RXFP-1 agonist or mimetic) to the woman through the 1st trimester of pregnancy.

### Claim 16 (depends on 9)

The method according to claim 9, wherein the placental syndrome is preeclampsia.

### Claim 17 (depends on 9)

The method according to claim 9, wherein step (a) comprises:
obtaining a biological sample from a woman;
quantitatively determining the amount of one or more nucleic acid species or corresponding proteins or activities in the biological sample obtained from the woman that hybridize with any one or more probe set ID Nos: 207016_s_at; 231040_at; 236514_at; 242868_at; 1568736_s_at; 202363_at; 204041_at; 210164_at; 205291_at; 205495_s_at; 231798_at; 217143_s_at; 227238_at; 206785_s_at; 205992_s_at; 209763_at; 205445_at; 229839_at; 223786_at; 227816_at; 204741_at; 235019_at; 205493_s_at; 205067_at; 204580_at; 205870_at; 230748_at; 213818_x_at; 214702_at; 202768_at; 203592_s_at; 206067_s_at; 205302_at; 215388_s_at; 217767_at; 217552_x_at; 205654_at; 229902_at; 208084_at; 206638_at; 202917_s_at; and
comparing the amount of the nucleic acid species from the first step to a standard control representing the amount of the nucleic acid species in the corresponding sample from an average non-preeclamptic woman without symptoms of placental syndromes; wherein an increase and decrease in the amount of the nucleic acid species in the biological sample as compared to the standard control indicates an increased risk of developing placental syndromes, such as preeclampsia.

### Claim 18 (depends on 17)

The method according to claim 17, wherein step (a) further comprises the use of an immunoassay for (i) binding one or more polypeptide species in the biological sample to an antibody and quantitatively determining the amount of said one or more polypeptide species in said biological sample, and (ii) comparing the amount of the polypeptide species from step (i) to a standard control representing the amount of the polypeptide species in the corresponding sample from an average non-preeclamptic woman, wherein an increase or a decrease in the amount of the polypeptide species from the standard control indicates preeclampsia or an increased risk of developing preeclampsia.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said immunoassay is selected from the group consisting of: a radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), sandwich immunoassay, immunoradiometric assay and Western blot.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the biological sample can be blood, washing from the reproductive tract, urine, saliva, amniotic fluid, endometrial biopsy or chorionic villus.

### Claim 21 (depends on 9)

The method according to claim 9, wherein step (a) comprises:
obtaining a biological sample from a woman;
quantitatively determining the amount of endogenous relaxin in the biological sample; and
comparing the amount of the quantified amount of endogenous relaxin to a standard control representing the amount of the endogenous relaxin in the corresponding sample from an average non-preeclamptic woman without symptoms of placental syndromes; wherein an increase and decrease in the amount of the endogenous relaxin in the biological sample as compared to the standard control indicates an increased risk of developing placental syndromes, such as preeclampsia.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the step of quantitatively determining the amount of endogenous relaxin in the biological sample comprises determining the amount of one or more nucleic acid species in the biological sample that hybridize with any one or more probe set for RLN-1, RLN-2, RLN-3 and RXFP1.
